BIO-TECHNE Corp Share-based Payment Arrangement, Expense, Tax Benefit
BIO-TECHNE Corp (TECH) reported Share-based Payment Arrangement, Expense, Tax Benefit of $700.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2026-05-06
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for the quarter ending 2026-03-31 was $700.00K, a 75.00% increase year-over-year.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for the quarter ending 2025-12-31 was -$500.00K, a 150.00% decline year-over-year.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for the quarter ending 2025-09-30 was $500.00K, a 84.85% decline year-over-year.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for the quarter ending 2025-06-30 was -$200.00K, a 104.17% decline year-over-year.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for fiscal 2025 was $4.50M, a 75.54% decline from fiscal 2024.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for fiscal 2024 was $18.40M, a 49.59% increase from fiscal 2023.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for fiscal 2023 was $12.30M, a 58.02% decline from fiscal 2022.
- BIO-TECHNE Corp share-based payment arrangement, expense, tax benefit for fiscal 2022 was $29.30M, a 4.27% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 12 month |
|---|---|---|---|---|
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-06 | $200.00K derived: sum of 2 quarters · filed 2026-05-06 | $700.00K 10-Q · filed 2026-05-06 | $500.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | -$500.00K 10-Q · filed 2026-02-04 | $0.00 derived: sum of 2 quarters · filed 2026-02-04 | -$200.00K derived: sum of 3 quarters · filed 2026-02-04 | $200.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-09-30 | $500.00K 10-Q · filed 2025-11-05 | $300.00K derived: sum of 2 quarters · filed 2025-11-05 | $700.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-06-30 | -$200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $200.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.20M derived: sum of 3 quarters · filed 2026-05-06 | $4.50M 10-K · filed 2025-08-22 |
| 2025-03-31 | $400.00K 10-Q · filed 2026-05-06 | $1.40M derived: sum of 2 quarters · filed 2026-05-06 | $4.70M 10-Q · filed 2026-05-06 | $9.50M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.00M 10-Q · filed 2026-02-04 | $4.30M 10-Q · filed 2026-02-04 | $9.10M derived: sum of 3 quarters · filed 2026-02-04 | $11.00M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | $3.30M 10-Q · filed 2025-11-05 | $8.10M derived: sum of 2 quarters · filed 2025-11-05 | $10.00M derived: sum of 3 quarters · filed 2025-11-05 | $11.30M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $6.70M derived: sum of 2 quarters · filed 2025-08-22 | $8.00M derived: sum of 3 quarters · filed 2025-08-22 | $18.40M 10-K · filed 2025-08-22 |
| 2024-03-31 | $1.90M 10-Q · filed 2025-05-08 | $3.20M derived: sum of 2 quarters · filed 2025-05-08 | $13.60M 10-Q · filed 2025-05-08 | $16.40M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-12-31 | $1.30M 10-Q · filed 2025-02-06 | $11.70M 10-Q · filed 2025-02-06 | $14.50M derived: sum of 3 quarters · filed 2025-08-22 | $14.90M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-09-30 | $10.40M 10-Q · filed 2024-11-05 | $13.20M derived: sum of 2 quarters · filed 2025-08-22 | $13.60M derived: sum of 3 quarters · filed 2025-08-22 | $14.50M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-06-30 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $3.20M derived: sum of 2 quarters · filed 2025-08-22 | $4.10M derived: sum of 3 quarters · filed 2025-08-22 | $12.30M 10-K · filed 2025-08-22 |
| 2023-03-31 | $400.00K 10-Q · filed 2024-05-06 | $1.30M derived: sum of 2 quarters · filed 2024-05-06 | $9.50M 10-Q · filed 2024-05-06 | $11.10M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-12-31 | $900.00K 10-Q · filed 2024-02-07 | $9.10M 10-Q · filed 2024-02-07 | $10.70M derived: sum of 3 quarters · filed 2024-08-22 | $14.10M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-09-30 | $8.30M 10-Q · filed 2023-11-07 | $9.80M derived: sum of 2 quarters · filed 2024-08-22 | $13.20M derived: sum of 3 quarters · filed 2024-08-22 | $19.30M derived: sum of 4 quarters · filed 2024-08-22 |
| 2022-06-30 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-22 | $4.90M derived: sum of 2 quarters · filed 2024-08-22 | $11.00M derived: sum of 3 quarters · filed 2024-08-22 | $29.30M 10-K · filed 2024-08-22 |
| 2022-03-31 | $3.40M 10-Q · filed 2023-05-08 | $9.50M derived: sum of 2 quarters · filed 2023-05-08 | $27.80M 10-Q · filed 2023-05-08 | |
| 2021-12-31 | $6.10M 10-Q · filed 2023-02-07 | $24.40M 10-Q · filed 2023-02-07 | ||
| 2021-09-30 | $18.30M 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | $28.10M 10-K · filed 2023-08-23 | |||
| 2018-06-30 | $400.00K 10-K/A · filed 2019-11-06 | |||
| 2017-06-30 | $500.00K 10-K · filed 2017-09-07 | $500.00K 10-K/A · filed 2019-11-06 | ||
| 2016-06-30 | $600.00K 10-K · filed 2017-09-07 | $600.00K 10-K · filed 2018-08-27 | ||
| 2015-06-30 | $600.00K 10-K · filed 2017-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |